ArticleJACC. Case reports2025
Atypical Mechanism of Coronary Stenosis Due to TAVR in a Patient With Anomalous Coronary Anatomy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) in patients with abnormal coronary anatomy remains challenging. CASE SUMMARY: An 80-year-old man was referred to our hospital for TAVR. Computed tomography revealed an anomalous left coronary artery (LCA) originating from the right sinus of Valsalva. After TAVR, new coronary stenosis due to the compression by calcification at the sinus of Valsalva was confirmed by multimodality imaging. DISCUSSION: In patients with this anomaly, coronary stenosis could occur in places other than the coronary ostium after TAVR. Calcification at the Valsalva sinus could directly compress the LCA after TAVR in patients with this anomaly. TAVR using a balloon-expandable valve under coronary protection would be a secure strategy for patients with this anomaly. TAKE-HOME MESSAGE: Adequate valve choice with a prudent coronary protection strategy is important for TAVR in patients with the LCA originating from the right sinus of Valsalva.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.